Nucleic Acid Testing Market To Illustrate A Rising Growth, Size, Share -2026 in Healthcare Sector | Pathway Insight with Diagnostic and Therapeutic Uses By CMI
Nucleic acid testing (NAT) or nucleic acid amplification test (NAAT) is one of the advanced diagnostic tests increasingly gaining traction over conventional culture methods owing to high efficiency and accuracy. Furthermore, nucleic acid testing has potential application in various life threating diseases including cancer, infectious diseases, genetic and mitochondrial disorders, and also in development of personalized and precision medicine. NAT is an efficient diagnostic method, which significantly reduces the procedural time and consumption of reagents. Moreover, nucleic acid testing is increasingly being used for screening blood donation samples to reduce the risk of transfusion transmitted infections (TTIs), thus aiding growth of the nucleic acid testing market.
Request a FREE sample copy of – Nucleic Acid Testing market report click here: https://www.coherentmarketinsights.com/insight/request-sample/1644
Nucleic Acid Testing Market – Driver
Nucleic acid tests are extensively used for screening and diagnosis of various infectious diseases. Moreover, growing prevalence of infectious diseases and management of epidemics of new diseases has led to increasing demand for advanced diagnostic tests such as nucleic acid testing. For instance, according to the World Health Organization (WHO), in 2015, around 32,000 deaths were caused by tuberculosis, and around 3, 23,000 new cases of TB were registered in the European region. Furthermore, according to the Centers for Disease Control and Prevention (CDC), around 5,251 deaths due to influenza infection were registered in 2015, in the U.S. According to the National Ambulatory Medical Care Survey: 2015 data, 16.8 million visits to physicians’ offices for infectious and parasitic diseases were registered in the U.S. Nucleic acid testing (NAT) enables examination of various changes in gene sequence and copy number, and provides information regarding disease recurrence and possible condition of patients likely to respond to a particular treatment. Moreover, NAT can identify which patient has undergone inherited mutations, which eventually help to identify whether the patient is at an increased risk of developing cancer or not. Increasing incidence of cancer in various regions is a major factor driving the adoption of nucleic acid testing. For instance, according to the Cancer Atlas: 2017, an estimated 14.1 million new cancer cases were registered in 2012. Moreover, in 2017, India, China, and other East and Central Asian countries accounted for nearly half of the world’s new cancer cases and deaths. Furthermore, according to the same source, by 2025, an estimated 19.3 million new cancer cases and 11.4 million cancer deaths will occur in developing regions.
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 25% OFF On Any Research Report
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1644
Research funding by various government and private organizations for cancer treatment and increasing adoption of molecular and nucleic acid testing in cancer research programs to detect molecular genetic changes in single or multiple sequences of DNA or mutations are some of the factor that are expected to aid growth of the nucleic acid testing market in the near future. In 2016, National Cancer Institute (NCI) invested US$ 3.9 billion for cancer research activities which accounted for 70.8% of the overall NCI 2016 budget. The NCI invested around US$ 533 million in cancer detection and diagnostic research activities. Moreover, in 2016, NCI allocated 40.4% of its funds for Research Project Grants (RPGs). Furthermore, in 2017, NCI budget increased by US$ 454 million (8.7%) from previous year (2016) for research activities.
Nucleic Acid Testing Market – Restraint
The inability or difficulty of nucleic acid testing in obtaining quantitative results from a large pool of clinical sample, challenges with using NAT test for susceptibility testing, and higher cost of nucleic acid testing devices is expected to hamper growth of the nucleic acid testing market. According to data published in Asian Journal of Transfusion Science, in February 2014, NAT is highly sensitive and advanced technique, however, it is associated with high cost and requires dedicated infrastructure facility, equipment, consumables, and technical expertise.
Nucleic Acid Testing Market – Regional Analysis
On the basis of region, the global nucleic acid testing market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds a dominant position in the nucleic acid testing market, followed by Europe. This is owing to increasing research and development studies by various government and pharmaceutical organizations in infectious disease and cancer diagnosis in North America. For instance, in January 2018, University of Glasgow-led project received US$ 1.85 million funding, which is a part of Global Challenges Research Fund (GCRF). This project will develop new tests for parasitic diseases and rapid testing in remote locations to help enable rapid diagnosis, and rapid treatment of infectious disease. Furthermore, high prevalence and awareness of cancer among people is expected to aid growth of the nucleic acid testing market in this region. For instance, according to American Cancer Society, data findings, North America registered higher incidence of cancer in children compared to any other region, in 2012. Moreover, North America accounted for 13.1% of total estimated cases of cancer, in 2012 globally.
To get a detailed table of content (ToC), please click – https://www.coherentmarketinsights.com/ongoing-insight/toc/1644
Asia Pacific is expected to witness fastest growth in the nucleic acid testing market over the forecast period. This is due to growing demand for efficient and quick diagnostic testing, and increasing focus of major market players to expand their geographical reach in this region. For instance, in March 2013, Qiagen N.V. launched its careHPV test in China. careHPV is molecular diagnostic test designed to screen for high risk human papillomavirus (HPV) for low-resource settings such as areas lacking electricity, water or laboratories. Qiagen also gained the approval from China’s State Food and Drug Administration (SFDA) for careHPV in 2012.
Nucleic Acid Testing Market – Competitive Analysis
Key players in the nucleic acid testing market are Abbott Laboratories, Beckman Coulter, Inc., Becton, Dickinson and Company, BioMérieux SA, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Grifols, S.A., Illumina, Inc., Novartis Ag, Qiagen N.V., Quest Diagnostics Incorporated, Siemens Ag, and Tecan Group Ltd., among others. Players are focusing on inorganic growth strategies, in order to enhance their market share and remain competitive in the market. For instance, in January 2017, Grifols, S.A. acquired the NAT (Nucleic Acid Testing) donor screening unit from Hologic, Inc. for US$ 1,850 million. The acquisition enabled Grifols to strengthen its position in transfusion medicine through NAT technology.
Nucleic Acid Testing Market – Taxonomy
By Product Type
- Nucleic Acid Test Kits
- Polymerase Chain Reaction(PCR)
- Ligase Chain Reaction(LCR)
- Transcription–mediated Amplification (TMA)
- Whole Genome Sequencing
- Infectious Disease
- Forensic Testing
- Personalized Medicine
By End User
- Hospitals & Clinics
- Pathology Laboratories
- Academic & Research Organization
- North America
- Latin America
- Asia Pacific
- Middle East
Other Exclusive Reports:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire